Retina is a Marker for Cerebrovascular Heath

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT04753970

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 1/2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
  • Mayo Clinic Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04753970
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04753970. Randomized; no masking; primary purpose prevention. Start 2021-02-09 (actual); primary completion 2030-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Retina is a Marker for Cerebrovascular Heath
Condition
Cerebral Small Vessel Diseases
Condition
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
Condition
Cerebral Microbleeding
Condition
Sporadic White Matter Disease
Intervention (Drug)
Cilostazol
Lead sponsor
Mayo Clinic (class: other)

Record details

Record id
cardio:ct-nct04753970
Content hash
3a8c755a1511caf5ff4f6caf6b3f899e11e0fb7fe1ead00c975d47812c18524b